Adjunct ketamine treatment of depression in treatment‐resistant schizophrenia patients is unsatisfactory in pilot and secondary follow‐up studies

OBJECTIVE: To investigate the effects of adjunct ketamine treatment on chronic treatment‐resistant schizophrenia patients with treatment‐resistant depressive symptoms (CTRS‐TRD patients), including alterations in brain function. METHODS: Intravenous ketamine (0.5 mg/kg body weight) was administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuo, Chuanjun, Lin, Xiaodong, Tian, Hongjun, Liu, Sha, Bian, Haiman, Chen, Ce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218248/
https://www.ncbi.nlm.nih.gov/pubmed/32174025
http://dx.doi.org/10.1002/brb3.1600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218248/
https://www.ncbi.nlm.nih.gov/pubmed/32174025
http://dx.doi.org/10.1002/brb3.1600

Ejemplares similares